Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.7326/L19-0481 | DOI Listing |
Ann Intern Med
February 2020
The Warren Alpert Medical School of Brown University and Lifespan Cardiovascular Institute, Providence, Rhode Island (M.G.).
J Med Toxicol
December 2016
Department of Emergency Medicine, Division of Medical Toxicology, Carolinas Medical Center, Charlotte, NC, USA.
Animal studies and human case reports show promise in using lipid rescue to treat refractory calcium channel antagonist toxicity. However, the majority of research and clinical experience has focused on non-dihydropyridine agents. Thus, we sought to investigate the value of lipid emulsion (ILE) therapy for dihydropyridine-induced shock.
View Article and Find Full Text PDFClin Toxicol (Phila)
October 2010
Emergency Medicine Department, Regions Hospital, St. Paul, MN 55101, USA.
Introduction: Vasopressors are commonly used for calcium channel blocker (CCB)-induced cardiogenic shock after calcium and high-dose insulin (HDI). Vasopressor therapy is frequently used in combination with HDI to increase blood pressure and improve outcome. However, no studies have compared the efficacy of HDI to the combination of a vasopressor and HDI in dihydropyridine overdose.
View Article and Find Full Text PDFCirc Shock
December 1991
Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada.
The actions of Platelet-Activating Factor (PAF) on isolated rat hearts were investigated. In a dose-dependent manner PAF decreased peak systolic pressure and maximum rate of rise of intraventricular pressure (+dP/dt(max]. PAF dose-dependently decreased coronary flow, prolonged the P-R interval of the EKG, and decreased heart rate.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!